

Cite as: D. Pan *et al.*, *Science*  
10.1126/science.aao1710 (2018).

# A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing

Deng Pan,<sup>1\*</sup> Aya Kobayashi,<sup>1\*</sup> Peng Jiang,<sup>2\*</sup> Lucas Ferrari de Andrade,<sup>1</sup> Rong En Tay,<sup>1</sup> Adrienne Luoma,<sup>1</sup> Daphne Tsoucas,<sup>2</sup> Xintao Qiu,<sup>3</sup> Klothilda Lim,<sup>3</sup> Prakash Rao,<sup>3†</sup> Henry W. Long,<sup>3</sup> Guo-Cheng Yuan,<sup>2</sup> John Doench,<sup>4</sup> Myles Brown,<sup>3</sup> Shirley Liu,<sup>2‡</sup> Kai W. Wucherpfennig<sup>1,5‡</sup>

<sup>1</sup>Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. <sup>2</sup>Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. <sup>3</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA. <sup>4</sup>Genetic Perturbation Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. <sup>5</sup>Department of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115, USA.

\*These authors contributed equally to this work. †Present address: Harvard University Office of Technology Development, Cambridge, MA 02138, USA.

‡Corresponding author. Email: kai\_wucherpfennig@dfci.harvard.edu (K.W.W); xslu@jimmy.harvard.edu (S.L.)

Many human cancers are resistant to immunotherapy for reasons that are poorly understood. We used a genome-scale CRISPR/Cas9 screen to identify mechanisms of tumor cell resistance to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. Inactivation of >100 genes sensitized mouse B16F10 melanoma cells to killing by T cells, including *Pbrm1*, *Arid2* and *Brd7*, which encode components of the PBAF form of the SWI/SNF chromatin remodeling complex. Loss of PBAF function increased tumor cell sensitivity to interferon- $\gamma$ , resulting in enhanced secretion of chemokines that recruit effector T cells. Treatment-resistant tumors became responsive to immunotherapy when *Pbrm1* was inactivated. In many human cancers, expression of *PBRM1* and *ARID2* inversely correlated with expression of T cell cytotoxicity genes, and *Pbrm1*-deficient murine melanomas were more strongly infiltrated by cytotoxic T cells.

Cancer immunotherapies that target inhibitory receptors on T cells including the PD-1 receptor, can induce durable responses, but the majority of patients do not respond (1). The mechanisms that determine resistance to these immunotherapies remain poorly understood. Cytotoxic T cells are key effectors of tumor immunity based on their ability to detect and kill transformed cells following T cell receptor (TCR) recognition of peptide antigens bound to MHC class I proteins (2). T cell-mediated cytotoxicity can be remarkably efficient, but it is diminished when MHC class I expression by tumor cells is reduced. Cytotoxicity is also inhibited when tumor cells express PD-L1, the ligand for the PD-1 receptor on T cells (3). We hypothesized that sensitivity and resistance of tumor cells to T cell-mediated attack is dynamically regulated by multiple pathways in tumor cells that could represent novel targets for immunotherapy.

## Discovery of tumor cell-intrinsic genes regulating sensitivity and resistance to T cell-mediated killing

Tumor cells transduced with a genome-scale gRNA library were subjected to selection with cytotoxic T cells to identify genes that controlled resistance to T cell-mediated killing (Fig. 1A). We selected the murine B16F10 melanoma cell line for this screen because it is resistant to checkpoint blockade with antibodies targeting the PD-1 and/or CTLA-4 receptors (4, 5). Inactivation of resistance genes resulted in depletion of the corresponding gRNAs, but such depletion could only

be detected with sufficient sensitivity when most tumor cells had sufficient Cas9 activity. We therefore selected a B16F10-Cas9 clone with high editing efficiency (fig. S1) and tested it with positive controls that were either more resistant (*B2m*<sup>-/-</sup>) or sensitive (*Cd274*<sup>-/-</sup>) to T cell-mediated cytotoxicity (fig. S2). This B16F10-Cas9 clone was then transduced with a genome-scale gRNA library in a lentiviral vector (6). Selection was performed either with Pmel-1 T cells which have a relatively low TCR affinity for an endogenous melanoma antigen (7) or high-affinity OT-I T cells (8). Edited tumor cells were selected by three-day co-culture with Pmel-1 CD8 T cells (or one day for OT-I T cells), and the representation of all gRNAs was quantified by Illumina sequencing of the gRNA cassette (Fig. 1A). The specificity of gRNA enrichment/depletion was demonstrated by comparing selection with tumor-specific T cells versus control T cells of irrelevant specificity (fig. S3). This comparison also controlled for potential effects of gRNAs on cell proliferation/viability.

A number of genes known to be essential for T cell-mediated tumor immunity were identified among the enriched gRNAs in both Pmel-1 and OT-1 screens (Fig. 1B, fig. S4A, tables S1-2), including key genes in the MHC class I and IFN $\gamma$  signaling pathways (9-11). Mutations in both MHC and interferon pathway genes were shown to confer resistance to cancer immunotherapy (12, 13). T cell-based CRISPR/Cas9 screens have been described by two other la-

laboratories. One of these studies performed an in vivo screen covering 2,368 murine genes and highlighted the phosphatase *Ptpn2* as a novel target for immunotherapy (14). The second study focused on human tumor cells and T cells and reported that mutations in *APLNR* render tumor cells resistant to T cell-mediated cytotoxicity (15). Our approach emphasized sensitive detection of depleted gRNAs in a genome-wide manner, which allowed us to discover additional mechanisms conferring resistance to immunotherapy.

A striking result was that gRNAs were depleted for a large number of genes (table S1-2), indicating that inactivation of these genes sensitized tumor cells to T cell-mediated killing. Top genes in this group included known negative immune regulators including *Cd274* (encoding PD-L1 (16, 17)), *Ptpn2* (18) and *Serpinb9* (19) (Fig. 1C, fig. S4B). However, the vast majority of identified genes had not been previously implicated in resistance to T cell-mediated killing (tables S1-2).

### Pathways regulating resistance of tumor cells to T cell-mediated cytotoxicity

We performed gene set enrichment analysis to identify known gene sets/pathways for genes corresponding to enriched or depleted gRNA (tables S3 and S4). Five negative regulators of the Ras/MAP kinase pathway were identified among enriched gRNAs including *Nf1* (20), *Dusp6* (21), *Spre1* (22), *Rasa2* (23) and *SPOP* (24) (Fig. 1D). Ras pathway activation is very common among human cancers and may not only promote tumor cell growth but also attenuate tumor immunity. Braf is immediately downstream of Ras, and small molecule inhibitors of mutant BRAF<sup>V600E</sup> elicit stronger cytotoxic T cell responses in melanoma patients and murine tumor models (25–27).

Analysis of depleted gRNAs revealed a number of resistance pathways to T cell-mediated killing (Fig. 1C, D and table S4). Interestingly, all three unique components of a SWI/SNF chromatin remodeling complex referred to as the PBAF complex (28, 29) were strongly depleted (*Arid2*, *Pbrm1* and *Brd7*), providing strong evidence that this complex conferred resistance to T cell-mediated killing (Fig. 1D). We also identified resistance genes in the NF- $\kappa$ B pathway (30) (*Otulin*, *Rela*, *Ikkkg*, *Ikkkb*, *Rnf31* and *Sharpin*) and key metabolic pathways, including mTORC1 (*RragA*, *RragC* and *Lamtor1* which are required for mTORC1 recruitment to lysosomes (31)), glycolysis (including *Nsdhl*, *Gne*, *Gale*, *Ero1l* and *Cd44*) and nicotinate/nicotinamide metabolism (including *Nadk* and *Nampt*). The NF- $\kappa$ B pathway was also identified as a resistance mechanism by Manguso *et al.* (14). Control experiments demonstrated that inactivation of such genes did not merely increase sensitivity to cell death; inactivation of representative genes (*Otulin*, *Dusp6* or *Nf1*) in B16F10-Cas9 cells did not render them more sen-

sitive to doxorubicin induced cell death (fig. S5). The majority of identified genes (253 of 313 genes) were validated in a secondary screen (fig. S6) which also confirmed the major pathways described above (fig. S7).

### Clinical relevance of PBAF complex to tumor immunity

We used TCGA RNA-seq datasets and TIMER (32) to examine the relevance of the CRISPR screen (fig. S8) and PBAF complex in human cancers. We found that mRNA levels of *ARID2* and *PBRM1* negatively correlated with *GZMB* and *PRF1* mRNA levels in many human cancer types (Fig. 2A, fig. S9A-B and table S5), suggesting that lower expression of *ARID2* and *PBRM1* is correlated with higher cytotoxic activity contributed by CD8 T cells (fig. S9C-D) in human cancers. This correlation was not merely explained by the degree of CD8 T cell infiltration because *ARID2* and *PBRM1* mRNA levels were also negatively associated with the *GZMB/CD8A* ratio (Fig. 2B). In addition, we found that low *ARID2* mRNA levels were associated with a substantial survival benefit in melanoma patients, but only for those tumors with a higher degree of infiltration by CD8 T cells (based on CD8 expression) (Fig. 2C). These data suggest that *ARID2* and *PBRM1* affect tumor immunity in a variety of human cancers.

### Relevance of PBAF complex to immune checkpoint blockade therapy

The SWI/SNF complex regulates chromatin accessibility for transcription factors. The BAF version of SWI/SNF induces dissociation of Polycomb repressive complex 1 and 2 (PRC1 and PRC2) (33), but the PBAF complex may operate through a different biochemical mechanism. The two complexes share core subunits, but unique components are *ARID1A/B* for the BAF (BRG1-associated factors) complex as well as *ARID2*, *PBRM1* and *BRD7* for the PBAF complex (Fig. 3A) (28). To validate the role of the PBAF complex in regulating sensitivity to T cell-mediated killing, we generated B16F10 tumor cell lines in which the three genes of the PBAF complex were individually mutated by CRISPR/Cas9. Western blotting experiments confirmed diminished levels of the corresponding proteins in the mutant cell lines (Fig. 3B). Inactivation of *Arid2* diminished protein levels of *Brd7* and *Pbrm1*, consistent with a prior study (34), while inactivation of *Pbrm1* did not affect protein levels of *Arid2* or *Brd7*. Partial complexes with some chromatin remodeling activity may therefore remain in some of these knockout cell lines. Co-culture of *Arid2*, *Pbrm1* or *Brd7* mutant tumor cells with cytotoxic T cells resulted in enhanced depletion of PBAF mutant cell lines compared to B16F10-Cas9 cells transduced with a control gRNA (referred to as control B16F10 tumor cells) in a three-day co-culture assay (Fig. 3C). However, inactivation of *Arid2*, *Pbrm1* or *Brd7* genes did not alter cell proliferation over a two-week period (fig. S10A).

B16F10 tumor cells are resistant to checkpoint blockade with PD-1 and/or CTLA-4 antibodies, and we therefore examined whether inactivation of *Pbrm1* would render B16F10 tumor cells sensitive to checkpoint blockade. PD-1 plus CTLA-4 antibodies conferred therapeutic benefit in mice bearing *Pbrm1* mutant B16F10 tumors but this treatment was ineffective against control B16F10 tumors (Fig. 3D-E and fig. S10B-C). Significantly increased numbers of CD45+ immune cells, CD4 and CD8 T cells, as well as granzyme B+ CD8 T cells were present in *Pbrm1* deficient compared to control B16F10 tumors treated with PD-1 plus CTLA-4 checkpoint blockade (Fig. 3F and fig. S10D). Single-cell RNA-seq analysis of sorted CD45+ immune cells showed that gene expression signatures associated with productive anti-tumor immunity (IFN $\gamma$  response, IFN $\alpha$  response and TNF $\alpha$  signaling via NF- $\kappa$ B) were significantly enriched in *Pbrm1* deficient compared to control B16F10 tumors for both myeloid cells (dendritic cells and M1-like macrophages) as well as lymphoid cells (T cells and NK cells) (fig. S11A-C). These single cell data also identified an increased percentage of dendritic cells and a higher ratio of tumor-inhibitory M1-like macrophages to tumor-promoting M2-like macrophages in *Pbrm1* deficient compared to control B16F10 tumors (fig. S11D). Thus, inactivation of *Pbrm1* not only sensitizes tumor cells to T cell-mediated cytotoxicity but also results in a more favorable tumor microenvironment.

### Regulation of IFN $\gamma$ and mTORC1 pathways by the PBAF complex

To investigate the molecular mechanisms by which the PBAF complex regulates the sensitivity of B16F10 tumor cells to T cell-mediated killing, we examined the transcriptome of PBAF deficient B16F10 cells by RNA-seq. *Arid2* and *Pbrm1* deficient B16F10 cells shared similar gene expression profiles (fig. S12A-B), consistent with their critical role in the PBAF complex. The transcriptome of *Brd7* mutant B16F10 cells was more distinct, suggesting that *Brd7* may also have PBAF-independent functions (fig. S12A). mRNAs for a number of metabolic pathways were concordantly downregulated in *Arid2* and *Pbrm1* mutant cells compared to control B16F10 tumor cells, in particular gene sets associated with mTORC1 activation and cholesterol homeostasis (fig. S12C-D and fig. S13). mTORC1 was also a major resistance pathway for T cell-mediated cytotoxicity in the CRISPR/Cas9 screen (Fig. 1D).

Silencing of BAF200 (*Arid2*) with a siRNA was shown to reduce the expression of Interferon Induced Transmembrane Protein 1 (IFITM1) by IFN $\alpha$ , but not other interferon-regulated genes (34). We systematically examined whether the PBAF complex regulates gene expression in response to IFN $\gamma$ , given the importance of this T cell-derived cytokine

for tumor immunity (12). RNA-seq analysis showed that gene sets related to IFN $\gamma$  and IFN $\alpha$  response were significantly enriched among genes concordantly upregulated in *Arid2* and *Pbrm1* deficient cells compared to B16F10 control cells treated with IFN $\gamma$  (Fig. 4A-B), suggesting that *Arid2* and *Pbrm1* suppressed the expression of IFN $\gamma$  responsive genes. Many of the IFN $\gamma$  responsive genes suppressed by *Arid2* and *Pbrm1* were relevant to innate immunity or encoded chemokines (*Cxcl9* and *Cxcl10*) (Fig. 4C) (35). *Pbrm1* deficient tumor cells also secreted substantially larger amounts of Cxcl9 and Cxcl10 compared to control B16F10 cells following IFN $\gamma$  stimulation (Fig. 4D-F) which are key chemokines for recruitment of effector T cells that express the Cxcr3 chemokine receptor (35). *Arid2* deficient cells had significantly increased surface levels of H2-K<sup>b</sup> over a range of IFN $\gamma$  concentrations compared to control B16F10 cells. Also, all three mutants showed increased surface levels of PD-L1 in response to IFN $\gamma$  (fig. S14). *Brd7* and *Pbrm1* deficient cells only showed enhanced surface expression of PD-L1 but not H2-K<sup>b</sup> in response to IFN $\gamma$  stimulation (fig. S14) which may be due to partial complexes that retain some activity. These data demonstrate that *Arid2* and *Pbrm1* attenuate the responsiveness of B16F10 tumor cells to IFN $\gamma$ , a key cytokine for the interaction of tumor cells and T cells.

### The PBAF complex regulates chromatin accessibility of IFN $\gamma$ -induced genes

The major function of the SWI/SNF complex is to regulate chromatin accessibility for transcription factors. We therefore performed ATAC-seq to directly assess chromatin accessibility in *Pbrm1* deficient and control B16F10 tumor cells with and without IFN $\gamma$  treatment for 24 hours. Following IFN $\gamma$  treatment, a substantially larger number of genomic sites were accessible in *Pbrm1* deficient than control B16F10 cells, consistent with the RNA-seq data (Fig. 5A). Sites in cluster 1 (648 sites) were more accessible prior to IFN $\gamma$  treatment in *Pbrm1* deficient compared to control cells, suggesting that the corresponding genes were poised to respond to IFN $\gamma$  (Fig. 5B-C, fig. S15A). Also, 2,708 sites (cluster III) showed enhanced accessibility following IFN $\gamma$  exposure in *Pbrm1* mutant compared to control B16F10 cells, but their accessibility was similar between the two cell lines in the absence of IFN $\gamma$  (Fig. 5B-C and fig. S15B). Motif and target gene prediction analysis suggests these sites were highly enriched with IRF motifs and associated with IFN regulated genes (fig. S15C-E). Thus, inactivation of *Pbrm1* enhances chromatin accessibility for transcription factors at promoters/enhancers of many IFN $\gamma$ -induced genes.

### Discussion

These data demonstrate that resistance to T cell-mediated cytotoxicity is regulated by many genes and pathways in

tumor cells. The corresponding gene products represent targets for immunotherapy because inactivating mutations sensitize tumor cells to T cell-mediated attack. The interaction between T cells and tumor cells is dynamically regulated at many levels, including innate immune and metabolic pathways within tumor cells. The PBAF complex is of particular interest because it regulates chromatin accessibility for IFN $\gamma$  pathway within tumor cells and thereby increases resistance to T cell-mediated cytotoxicity.

The PBAF complex is a tumor suppressor and inactivating mutations in any of the three unique genes of this complex (*PBRM1*, *ARID2* and *BRD7*) are known to occur in a variety of human cancers (28). For example, inactivating mutations in *PBRM1* are prevalent in clear cell renal cancer (~41% of patients) (36). A study by Miao *et al.* in this issue demonstrates that *PBRM1* mutations in metastatic renal cancers are associated with improved clinical responses to PD-1/PD-L1 blockade (37). Mutations in *ARID2* and *BRD7* are also observed in a variety of other human cancers, including *ARID2* mutations in melanoma (38). Human tumors with inactivating mutations in *PBRM1*, *ARID2* and *BRD7* may therefore be more sensitive to PD-1 blockade as well as other forms of immunotherapy in which cytotoxic T cells serve as the main effector mechanism, including cancer vaccines and adoptive T cell therapies. This study provides a mechanistic understanding for these clinical findings by demonstrating that PBAF-deficient tumor cells are more sensitive to T cell-mediated cytotoxicity. We also show that PBAF-deficient tumor cells produce higher levels of chemokines (Cxcl9 and Cxcl10) in response to IFN $\gamma$ , resulting in more efficient recruitment of effector T cells into tumors (35).

The immunotherapy field has thus far emphasized the targeting of inhibitory receptors expressed by immune cells. We propose that targeting of tumor cell-intrinsic resistance mechanisms to T cell-mediated cytotoxicity will be important to extend the benefit of immunotherapy to larger patient populations, including cancers that thus far are refractory to immunotherapy.

## REFERENCES AND NOTES

1. P. Sharma, S. Hu-Lieskovan, J. A. Wargo, A. Ribas, Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. *Cell* **168**, 707–723 (2017). [doi:10.1016/j.cell.2017.01.017](https://doi.org/10.1016/j.cell.2017.01.017) Medline
2. N. Zhang, M. J. Bevan, CD8(+) T cells: Foot soldiers of the immune system. *Immunity* **35**, 161–168 (2011). [doi:10.1016/j.immuni.2011.07.010](https://doi.org/10.1016/j.immuni.2011.07.010) Medline
3. Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo, N. Minato, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. *Proc. Natl. Acad. Sci. U.S.A.* **99**, 12293–12297 (2002). [doi:10.1073/pnas.192461099](https://doi.org/10.1073/pnas.192461099) Medline
4. A. van Elsas, A. A. Hurwitz, J. P. Allison, Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. *J. Exp. Med.* **190**, 355–366 (1999). [doi:10.1084/jem.190.3.355](https://doi.org/10.1084/jem.190.3.355) Medline
5. S. Chen, L.-F. Lee, T. S. Fisher, B. Jessen, M. Elliott, W. Evering, K. Logronio, G. H. Tu, K. Tsaparikos, X. Li, H. Wang, C. Ying, M. Xiong, T. VanArsdale, J. C. Lin, Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model. *Cancer Immunol. Res.* **3**, 149–160 (2015). [doi:10.1158/2326-6066.CCR-14-0118](https://doi.org/10.1158/2326-6066.CCR-14-0118) Medline
6. J. G. Doench, N. Fusi, M. Sullender, M. Hegde, E. W. Vaimberg, K. F. Donovan, I. Smith, Z. Tothova, C. Wilen, R. Orchard, H. W. Virgin, J. Listgarten, D. E. Root, Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. *Nat. Biotechnol.* **34**, 184–191 (2016). [doi:10.1038/nbt.3437](https://doi.org/10.1038/nbt.3437) Medline
7. W. W. Overwijk, M. R. Theoret, S. E. Finkelstein, D. R. Surman, L. A. de Jong, F. A. Vyth-Dreese, T. A. DelleMijn, P. A. Antony, P. J. Spiess, D. C. Palmer, D. M. Heimann, C. A. Klebanoff, Z. Yu, L. N. Hwang, L. Feigenbaum, A. M. Kruisbeek, S. A. Rosenberg, N. P. Restifo, Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. *J. Exp. Med.* **198**, 569–580 (2003). [doi:10.1084/jem.20030590](https://doi.org/10.1084/jem.20030590) Medline
8. K. A. Hogquist, S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, F. R. Carbone, T cell receptor antagonist peptides induce positive selection. *Cell* **76**, 17–27 (1994). [doi:10.1016/0092-8674\(94\)90169-4](https://doi.org/10.1016/0092-8674(94)90169-4) Medline
9. J. S. Blum, P. A. Wearsch, P. Cresswell, Pathways of antigen processing. *Annu. Rev. Immunol.* **31**, 443–473 (2013). [doi:10.1146/annurev-immunol-032712-095910](https://doi.org/10.1146/annurev-immunol-032712-095910) Medline
10. K. S. Kobayashi, P. J. van den Elsen, NLR5: A key regulator of MHC class I-dependent immune responses. *Nat. Rev. Immunol.* **12**, 813–820 (2012). [doi:10.1038/nri3339](https://doi.org/10.1038/nri3339) Medline
11. B. S. Parker, J. Rautela, P. J. Hertzog, Antitumor actions of interferons: Implications for cancer therapy. *Nat. Rev. Cancer* **16**, 131–144 (2016). [doi:10.1038/nrc.2016.14](https://doi.org/10.1038/nrc.2016.14) Medline
12. J. Gao, L. Z. Shi, H. Zhao, J. Chen, L. Xiong, Q. He, T. Chen, J. Roszik, C. Bernatchez, S. E. Woodman, P.-L. Chen, P. Hwu, J. P. Allison, A. Futreal, J. A. Wargo, P. Sharma, Loss of IFN- $\gamma$  Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy. *Cell* **167**, 397–404.e9 (2016). [doi:10.1016/j.cell.2016.08.069](https://doi.org/10.1016/j.cell.2016.08.069) Medline
13. J. M. Zaretsky, A. Garcia-Diaz, D. S. Shin, H. Escuin-Ordinas, W. Hugo, S. Hu-Lieskovan, D. Y. Torrejon, G. Abril-Rodriguez, S. Sandoval, L. Barthly, J. Saco, B. Homet Moreno, R. Mezzadra, B. Chmielowski, K. Ruchalski, I. P. Shintaku, P. J. Sanchez, C. Puig-Saus, G. Cherry, E. Seja, X. Kong, J. Pang, B. Berent-Maoz, B. Comin-Anduix, T. G. Graeber, P. C. Tumeh, T. N. M. Schumacher, R. S. Lo, A. Ribas, Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. *N. Engl. J. Med.* **375**, 819–829 (2016). [doi:10.1056/NEJMoa1604958](https://doi.org/10.1056/NEJMoa1604958) Medline
14. R. T. Manguso, H. W. Pope, M. D. Zimmer, F. D. Brown, K. B. Yates, B. C. Miller, N. B. Collins, K. Bi, M. W. LaFleur, V. R. Juneja, S. A. Weiss, J. Lo, D. E. Fisher, D. Miao, E. Van Allen, D. E. Root, A. H. Sharpe, J. G. Doench, W. N. Haining, In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. *Nature* **547**, 413–418 (2017). [doi:10.1038/nature23270](https://doi.org/10.1038/nature23270) Medline
15. K. G. Patel, J. R. Swartz, Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry. *Bioconjug. Chem.* **22**, 376–387 (2011). [doi:10.1021/bc100367u](https://doi.org/10.1021/bc100367u) Medline
16. H. Dong, G. Zhu, K. Tamada, L. Chen, B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. *Nat. Med.* **5**, 1365–1369 (1999). [doi:10.1038/70932](https://doi.org/10.1038/70932) Medline
17. G. J. Freeman, A. J. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. J. Fitz, N. Malenkovich, T. Okazaki, M. C. Byrne, H. F. Horton, L. Fouser, L. Carter, V. Ling, M. R. Bowman, B. M. Carreno, M. Collins, C. R. Wood, T. Honjo, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. *J. Exp. Med.* **192**, 1027–1034 (2000). [doi:10.1084/jem.192.7.1027](https://doi.org/10.1084/jem.192.7.1027) Medline
18. M. Kleppe, J. Soulier, V. Asnafi, N. Mentens, T. Hornakova, L. Knoop, S. Constantinescu, F. Sigaux, J. P. Meijerink, P. Vandenberghe, M. Tartaglia, R. Foa, E. Macintyre, T. Haferlach, J. Cools, PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia. *Blood* **117**, 7090–7098 (2011). [doi:10.1182/blood-2010-10-314286](https://doi.org/10.1182/blood-2010-10-314286) Medline
19. D. Kaiserman, P. I. Bird, Control of granzymes by serpins. *Cell Death Differ.* **17**, 586–595 (2010). [doi:10.1038/cdd.2009.169](https://doi.org/10.1038/cdd.2009.169) Medline

20. N. Ratner, S. J. Miller, A RASopathy gene commonly mutated in cancer: The neurofibromatosis type 1 tumour suppressor. *Nat. Rev. Cancer* **15**, 290–301 (2015). [doi:10.1038/nrc.3911](https://doi.org/10.1038/nrc.3911) [Medline](#)
21. S. Messina, L. Frati, C. Leonetti, C. Zuchegna, E. Di Zazzo, A. Calogero, A. Porcellini, Dual-specificity phosphatase DUSP6 has tumor-promoting properties in human glioblastomas. *Oncogene* **30**, 3813–3820 (2011). [doi:10.1038/onc.2011.99](https://doi.org/10.1038/onc.2011.99) [Medline](#)
22. T. N. Phoenix, S. Temple, Spred1, a negative regulator of Ras-MAPK-ERK, is enriched in CNS germinal zones, dampens NSC proliferation, and maintains ventricular zone structure. *Genes Dev.* **24**, 45–56 (2010). [doi:10.1101/gad.1839510](https://doi.org/10.1101/gad.1839510) [Medline](#)
23. R. Arafeh, N. Qutob, R. Emmanuel, A. Keren-Paz, J. Madore, A. Elkhoulou, J. S. Wilmott, J. J. Gartner, A. Di Pizio, S. Winograd-Katz, S. Sindiri, R. Rotkopf, K. Dutton-Regester, P. Johansson, A. L. Pritchard, N. Waddell, V. K. Hill, J. C. Lin, Y. Hevroni, S. A. Rosenberg, J. Khan, S. Ben-Dor, M. Y. Niv, I. Ulitsky, G. J. Mann, R. A. Scolyer, N. K. Hayward, Y. Samuels, Recurrent inactivating RASA2 mutations in melanoma. *Nat. Genet.* **47**, 1408–1410 (2015). [doi:10.1038/ng.3427](https://doi.org/10.1038/ng.3427) [Medline](#)
24. G. Li, W. Ci, S. Karmakar, K. Chen, R. Dhar, Z. Fan, Z. Guo, J. Zhang, Y. Ke, L. Wang, M. Zhuang, S. Hu, X. Li, L. Zhou, X. Li, M. F. Calabrese, E. R. Watson, S. M. Prasad, C. Rinker-Schaeffer, S. E. Eggner, T. Stricker, Y. Tian, B. A. Schulman, J. Liu, K. P. White, SPOP promotes tumorigenesis by acting as a key regulatory hub in kidney cancer. *Cancer Cell* **25**, 455–468 (2014). [doi:10.1016/j.ccr.2014.02.007](https://doi.org/10.1016/j.ccr.2014.02.007) [Medline](#)
25. D. T. Frederick, A. Piris, A. P. Cogdill, Z. A. Cooper, C. Lezcano, C. R. Ferrone, D. Mitra, A. Boni, L. P. Newton, C. Liu, W. Peng, R. J. Sullivan, D. P. Lawrence, F. S. Hodi, W. W. Overwijk, G. Lizée, G. F. Murphy, P. Hwu, K. T. Flaherty, D. E. Fisher, J. A. Wargo, BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. *Clin. Cancer Res.* **19**, 1225–1231 (2013). [doi:10.1158/1078-0432.CCR-12-1630](https://doi.org/10.1158/1078-0432.CCR-12-1630) [Medline](#)
26. P. J. R. Ebert, J. Cheung, Y. Yang, E. McNamara, R. Hong, M. Moskalenko, S. E. Gould, H. Maecker, B. A. Irving, J. M. Kim, M. Belvin, I. Mellman, MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. *Immunity* **44**, 609–621 (2016). [doi:10.1016/j.immuni.2016.01.024](https://doi.org/10.1016/j.immuni.2016.01.024) [Medline](#)
27. R. C. Koya, S. Mok, N. Otte, K. J. Blacketer, B. Comin-Anduix, P. C. Tumeh, A. Minasyan, N. A. Graham, T. G. Graeber, T. Chodon, A. Ribas, BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. *Cancer Res.* **72**, 3928–3937 (2012). [doi:10.1158/0008-5472.CAN-11-2837](https://doi.org/10.1158/0008-5472.CAN-11-2837) [Medline](#)
28. C. Kadoch, G. R. Crabtree, Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics. *Sci. Adv.* **1**, e1500447 (2015). [doi:10.1126/sciadv.1500447](https://doi.org/10.1126/sciadv.1500447) [Medline](#)
29. B. Lemon, C. Inouye, D. S. King, R. Tjian, Selectivity of chromatin-remodelling cofactors for ligand-activated transcription. *Nature* **414**, 924–928 (2001). [doi:10.1038/414924a](https://doi.org/10.1038/414924a) [Medline](#)
30. Q. Zhang, M. J. Lenardo, D. Baltimore, 30 Years of NF- $\kappa$ B: A Blossoming of Relevance to Human Pathobiology. *Cell* **168**, 37–57 (2017). [doi:10.1016/j.cell.2016.12.012](https://doi.org/10.1016/j.cell.2016.12.012) [Medline](#)
31. Y. Sancak, L. Bar-Peled, R. Zoncu, A. L. Markhard, S. Nada, D. M. Sabatini, Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids. *Cell* **141**, 290–303 (2010). [doi:10.1016/j.cell.2010.02.024](https://doi.org/10.1016/j.cell.2010.02.024) [Medline](#)
32. B. Li, E. Severson, J.-C. Pignon, H. Zhao, T. Li, J. Novak, P. Jiang, H. Shen, J. C. Aster, S. Rodig, S. Signoretti, J. S. Liu, X. S. Liu, Comprehensive analyses of tumor immunity: Implications for cancer immunotherapy. *Genome Biol.* **17**, 174 (2016). [doi:10.1186/s13059-016-1028-7](https://doi.org/10.1186/s13059-016-1028-7) [Medline](#)
33. C. Kadoch, R. T. Williams, J. P. Calarco, E. L. Miller, C. M. Weber, S. M. G. Braun, J. L. Pulice, E. J. Chory, G. R. Crabtree, Dynamics of BAF-Polycomb complex opposition on heterochromatin in normal and oncogenic states. *Nat. Genet.* **49**, 213–222 (2017). [doi:10.1038/ng.3734](https://doi.org/10.1038/ng.3734) [Medline](#)
34. Z. Yan, K. Cui, D. M. Murray, C. Ling, Y. Xue, A. Gerstein, R. Parsons, K. Zhao, W. Wang, PBAF chromatin-remodeling complex requires a novel specificity subunit, BAF200, to regulate expression of selective interferon-responsive genes. *Genes Dev.* **19**, 1662–1667 (2005). [doi:10.1101/gad.1323805](https://doi.org/10.1101/gad.1323805) [Medline](#)
35. J. R. Groom, A. D. Luster, CXCR3 ligands: Redundant, collaborative and antagonistic functions. *Immunol. Cell Biol.* **89**, 207–215 (2011). [doi:10.1038/icb.2010.158](https://doi.org/10.1038/icb.2010.158) [Medline](#)
36. I. Varela, P. Tarpey, K. Raine, D. Huang, C. K. Ong, P. Stephens, H. Davies, D. Jones, M. L. Lin, J. Teague, G. Bignell, A. Butler, J. Cho, G. L. Dalglish, D. Galappaththige, C. Greenman, C. Hardy, M. Jia, C. Latimer, K. W. Lau, J. Marshall, S. McLaren, A. Menzies, L. Mudie, L. Stebbings, D. A. Largaespada, L. F. Wessels, S. Richard, R. J. Kahnoski, J. Anema, D. A. Tuveson, P. A. Perez-Mancera, V. Mustonen, A. Fischer, D. J. Adams, A. Rust, W. Chan-on, C. Subimerb, K. Dykema, K. Furge, P. J. Campbell, B. T. Teh, M. R. Stratton, P. A. Futreal, Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. *Nature* **469**, 539–542 (2011). [doi:10.1038/nature09639](https://doi.org/10.1038/nature09639) [Medline](#)
37. D. Miao *et al.*, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma. *Science* (2017).
38. E. Hodis, I. R. Watson, G. V. Kryukov, S. T. Arold, M. Imielinski, J.-P. Theurillat, E. Nickerson, D. Auclair, L. Li, C. Place, D. Dicara, A. H. Ramos, M. S. Lawrence, K. Cibulskis, A. Sivachenko, D. Voet, G. Saksena, N. Stransky, R. C. Onofrio, W. Winckler, K. Ardlie, N. Wagle, J. Wargo, K. Chong, D. L. Morton, K. Stemke-Hale, G. Chen, M. Noble, M. Meyerson, J. E. Ladbury, M. A. Davies, J. E. Gershenwald, S. N. Wagner, D. S. B. Hoon, D. Schadendorf, E. S. Lander, S. B. Gabriel, G. Getz, L. A. Garraway, L. Chin, A landscape of driver mutations in melanoma. *Cell* **150**, 251–263 (2012). [doi:10.1016/j.cell.2012.06.024](https://doi.org/10.1016/j.cell.2012.06.024) [Medline](#)
39. S. Chen, N. E. Sanjana, K. Zheng, O. Shalem, K. Lee, X. Shi, D. A. Scott, J. Song, J. Q. Pan, R. Weissleder, H. Lee, F. Zhang, P. A. Sharp, Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. *Cell* **160**, 1246–1260 (2015). [doi:10.1016/j.cell.2015.02.038](https://doi.org/10.1016/j.cell.2015.02.038) [Medline](#)
40. W. Li, H. Xu, T. Xiao, L. Cong, M. I. Love, F. Zhang, R. A. Irizarry, J. S. Liu, M. Brown, X. S. Liu, MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens. *Genome Biol.* **15**, 554 (2014). [doi:10.1186/s13059-014-0554-4](https://doi.org/10.1186/s13059-014-0554-4) [Medline](#)
41. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014). [doi:10.1186/s13059-014-0550-8](https://doi.org/10.1186/s13059-014-0550-8) [Medline](#)
42. C. Trapnell, B. A. Williams, G. Pertea, A. Mortazavi, G. Kwan, M. J. van Baren, S. L. Salzberg, B. J. Wold, L. Pachter, Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat. Biotechnol.* **28**, 511–515 (2010). [doi:10.1038/nbt.1621](https://doi.org/10.1038/nbt.1621) [Medline](#)
43. J. D. Buenrostro, B. Wu, H. Y. Chang, W. J. Greenleaf, ATAC-seq: A Method for Assaying Chromatin Accessibility Genome-Wide. *Curr. Protoc. Mol. Biol.* **109**, 1–9 (2015). [doi:10.1002/0471142727.mb2129s109](https://doi.org/10.1002/0471142727.mb2129s109) [Medline](#)
44. J. D. Buenrostro, P. G. Giresi, L. C. Zaba, H. Y. Chang, W. J. Greenleaf, Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. *Nat. Methods* **10**, 1213–1218 (2013). [doi:10.1038/nmeth.2688](https://doi.org/10.1038/nmeth.2688) [Medline](#)
45. H. Li, R. Durbin, Fast and accurate short read alignment with Burrows-Wheeler transform. *Bioinformatics* **25**, 1754–1760 (2009). [doi:10.1093/bioinformatics/btp324](https://doi.org/10.1093/bioinformatics/btp324) [Medline](#)
46. Y. Zhang, T. Liu, C. A. Meyer, J. Eeckhoutte, D. S. Johnson, B. E. Bernstein, C. Nusbaum, R. M. Myers, M. Brown, W. Li, X. S. Liu, Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* **9**, R137 (2008). [doi:10.1186/gb-2008-9-9-r137](https://doi.org/10.1186/gb-2008-9-9-r137) [Medline](#)
47. S. Wang, H. Sun, J. Ma, C. Zang, C. Wang, J. Wang, Q. Tang, C. A. Meyer, Y. Zhang, X. S. Liu, Target analysis by integration of transcriptome and ChIP-seq data with BETA. *Nat. Protoc.* **8**, 2502–2515 (2013). [doi:10.1038/nprot.2013.150](https://doi.org/10.1038/nprot.2013.150) [Medline](#)
48. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 15545–15550 (2005). [doi:10.1073/pnas.0506580102](https://doi.org/10.1073/pnas.0506580102) [Medline](#)
49. V. K. Mootha, C. M. Lindgren, K.-F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver, E. Carlsson, M. Ridderstråle, E. Laurila, N. Houstis, M. J. Daly, N. Patterson, J. P. Mesirov, T. R. Golub, P. Tamayo, B. Spiegelman, E. S. Lander, J.

- N. Hirschhorn, D. Altshuler, L. C. Groop, PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. *Nat. Genet.* **34**, 267–273 (2003). [doi:10.1038/ng1180](https://doi.org/10.1038/ng1180) [Medline](#)
50. S. Heinz, C. Benner, N. Spann, E. Bertolino, Y. C. Lin, P. Laslo, J. X. Cheng, C. Murre, H. Singh, C. K. Glass, Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. *Mol. Cell* **38**, 576–589 (2010). [doi:10.1016/j.molcel.2010.05.004](https://doi.org/10.1016/j.molcel.2010.05.004) [Medline](#)

## ACKNOWLEDGMENTS

We thank the staff of the Center for Cancer Genome Discovery (CCGD) and the Molecular Biology Core Facility (MBCF) at Dana Farber Cancer Institute for DNA sequencing. D.P. is a Cancer Research Institute/Robertson Foundation Fellow; L.F.A. was funded by a Friends for Life Neuroblastoma Fellowship and R.E.T. was supported by an A\*STAR Graduate Fellowship. A.L. is a Research Fellow of the Training Program in Cancer Immunology at DFCI (NIH grant #: 1T32CA207021-01). This work was supported by a Transformative R01 grant from NCI, NIH (R01CA173750) and by a sponsored research agreement with Astellas Pharma. S.L. is a co-founder of and is on the Scientific Advisory Board of GV20 Oncotherapy, a precision cancer medicine company. S.L. is also on the Scientific Advisory Board of 3DMedCare and is a paid consultant for Genentech. J.D. is a paid consultant for Tango Therapeutics. K.W.W. and D.P. are inventors on patent application DFS-190.6 submitted by Dana-Farber Cancer Institute, which covers novel targets for cancer immunotherapy. RNA-seq data have been deposited at the Gene Expression Omnibus (GEO) under accession number GSE107670.

## SUPPLEMENTARY MATERIALS

[www.sciencemag.org/cgi/content/full/science.aao1710/DC1](http://www.sciencemag.org/cgi/content/full/science.aao1710/DC1)

Materials and Methods

Figs. S1 to S15

Tables S1 to S5


References (39–50)

21 June 2017; resubmitted 30 October 2017


Accepted 14 December 2017

Published online 4 January 2018


[10.1126/science.aao1710](https://doi.org/10.1126/science.aao1710)




**Fig. 1. Systematic discovery of genes and pathways regulating sensitivity and resistance of tumor cells to T cell-mediated killing.** (A) Screening strategy. Cas9-expressing B16F10 cells were transduced with a genomic-scale gRNA library (4 gRNAs/gene). Edited B16F10 cells were co-cultured with activated cytotoxic T cells followed by Illumina sequencing of gRNA representation. Specific selection was performed with Pmel-1 T cells (specific for gp100 melanoma antigen) or OT-I T cells (specific for Ova peptide). Control selection was performed with T cells of irrelevant specificity. (B) Top genes for enriched gRNAs from Pmel-1 screen. Candidate genes were plotted based on mean  $\log_2$  fold change of gRNA counts compared to control selection and p-values computed by MaGeCK. Dashed line indicates a FDR (False Discovery Rate) = 0.05. Annotated genes represent MHC class I (red), interferon (yellow) and Ras/MAPK (blue) pathways. (C) Top genes for depleted gRNAs from Pmel-1 screen. Genes related to PBAF form of SWI/SNF complex (red), NF- $\kappa$ B pathway (blue), mTORC1 pathway (yellow), and known negative immune regulators (green) were annotated. (D) Selected pathways and corresponding genes identified in the Pmel-1 screen. Color scale represents  $\log_2$  fold change of average gRNA representation.




**Fig. 2. Expression of ARID2 and PBRM1 is negatively correlated with T cell cytotoxicity markers in TCGA datasets.** (A) Correlation of ARID2 and PBRM1 mRNA levels with GZMB mRNA levels in indicated cancers. Volcano plot showing the Spearman's correlation and estimated significance of ARID2 (left) or PBRM1 (right) with GZMB mRNA levels from RNA-seq data across TCGA cancer types calculated by TIMER (Tumor Immune Estimation Resource) and adjusted for tumor purity (32). Each dot represents a cancer type in TCGA; red dots indicate significant correlations ( $p < 0.01$ ). (B) Analysis of ARID2 and PBRM1 mRNA levels in relationship to GZMB and CD8A as cytotoxicity and CD8 T cell infiltration markers, respectively. Spearman's correlation of ARID2 (left) and PBRM1 (right) mRNA levels to GZMB/CD8A mRNA ratio in TCGA melanoma dataset. (C) Correlation of ARID2 expression level with survival of melanoma patients depending on calculated level of CD8 T cell infiltration. All patients in TCGA melanoma study were divided according to the expression level of ARID2 (higher or lower than mean expression value of all patients). The impact of ARID2 expression level on survival is shown for patients whose tumors had higher (greater than one standard deviation) or lower (less than one standard deviation) expression of CD8  $[(\text{CD8A} + \text{CD8B})/2]$ .



**Fig. 3. Inactivation of PBAF complex sensitizes tumor cells to T cell-mediated killing and synergizes with checkpoint blockade therapy.** (A) Cartoon illustrating the composition of BAF and PBAF versions of SWI/SNF complex. (B) Western blot showing protein levels of Arid2, Brd7, Pbrm1 and Gapdh in control and indicated knockout cell lines. (C) GFP-positive *Arid2*, *Pbrm1* or *Brd7* deficient B16F10 cells were mixed with GFP-negative control B16F10 cells at approximately 1:1 ratio. Tumor cells were co-cultured with Pmel-1 T cells at indicated effector to target ratios for 3 days in triplicates; the fold change of % GFP+ tumor cells was determined by FACS. Two-way ANOVA was used to determine statistical significance (\*\*\*\* p < 0.0001). Values represents mean  $\pm$  SD. (D) Mice bearing control (n=10) or *Pbrm1*-deficient B16F10 tumors (n=10) were treated with  $\alpha$ -PD-1 (200 $\mu$ g/mouse) plus  $\alpha$ -CTLA-4 antibodies (100 $\mu$ g/mouse) and tumor size was measured. Two-way ANOVA was used to determine statistical significance for time points when all mice were viable for tumor measurement. (E) Survival of mice inoculated with control (n=10) or *Pbrm1*-deficient B16F10 cells (n=10) and treated with  $\alpha$ -PD-1 plus  $\alpha$ -CTLA-4 antibodies. Log-rank (Mantel-Cox) test was used to determine statistical significance. (F) Flow cytometric analysis of immune cell infiltration in *Pbrm1*-deficient and control B16F10 tumors. The number of CD45+, CD4+, CD8+ and Granzyme B+ CD8+ T cells was determined per gram of tumor. Mann-Whitney test was used to determine significance (\* p < 0.05, \*\* p < 0.01). Values represents mean  $\pm$  SD. Data in (C-F) are representative of two independent experiments.



**Fig. 4. Enhanced responsiveness to IFN $\gamma$  stimulation by *Arid2* and *Pbrm1* deficient tumor cells.** (A-C) RNA-seq analysis of *Arid2* or *Pbrm1* deficient cells and control B16F10 cells treated with IFN $\gamma$  (10ng/ml) for 24 hours. (A) Venn diagram showing differentially regulated mRNAs in the presence of IFN $\gamma$ . (B) Hallmark gene sets enriched for commonly up- or down-regulated mRNAs in both *Arid2* and *Pbrm1* deficient cells compared to control B16F10 cells in the presence of IFN $\gamma$  treatment (as shown in A). (C) Heat map showing expression value (z-score based on cufflink count) of interferon-responsive genes in control, *Arid2* and *Pbrm1* deficient B16F10 cells following IFN $\gamma$  treatment. (D-E) Cxcl9 mRNA level (D) and Cxcl9 protein secretion (E) comparing *Pbrm1*-deficient and control B16F10 tumor cells stimulated with IFN $\gamma$  (10ng/ml) for 24 hours. Values represents mean  $\pm$  SD. (F) Cxcl10 secretion by *Pbrm1*-deficient and control B16F10 tumor cells stimulated with IFN $\gamma$  (0, 0.5 and 1 ng/ml) for 24 hours. Values represents mean  $\pm$  SD. One-way ANOVA (D-E) and two-way ANOVA were used to determine significance (F). \*\*  $p < 0.01$ , \*\*\*\*  $p < 0.0001$ . Data in (D-F) are representative of two independent experiments.



**Fig. 5. Enhanced chromatin accessibility for IFN $\gamma$  responsive genes in *Pbrm1*-deficient tumor cells.** ATAC-seq was performed on *Pbrm1*-deficient and control B16F10 cells +/- IFN $\gamma$  stimulation (10ng/ml) for 24 hours. **(A)** Genome-wide analysis of differentially accessible chromatin sites ( $|\log_2$  fold change  $> 0.5$ ) following IFN $\gamma$  stimulation in control versus *Pbrm1*-deficient B16F10 tumor cells. **(B)** Venn diagram illustrating accessible sites gained following IFN $\gamma$  treatment in control (blue) and *Pbrm1*-deficient (red) cells. **(C)** Chromatin accessibility heat maps for all sites in clusters I (top panel) and III (bottom panel). Aggregated reads within 2kb of center of differentially accessible regions are shown above heat maps.

## A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

Deng Pan, Aya Kobayashi, Peng Jiang, Lucas Ferrari de Andrade, Rong En Tay, Adrienne Luoma, Daphne Tsoucas, Xintao Qiu, Klothilda Lim, Prakash Rao, Henry W. Long, Guo-Cheng Yuan, John Doench, Myles Brown, Shirley Liu and Kai W. Wucherpfennig

published online January 4, 2018

ARTICLE TOOLS	<a href="http://science.sciencemag.org/content/early/2018/01/03/science.aao1710">http://science.sciencemag.org/content/early/2018/01/03/science.aao1710</a>
SUPPLEMENTARY MATERIALS	<a href="http://science.sciencemag.org/content/suppl/2018/01/03/science.aao1710.DC1">http://science.sciencemag.org/content/suppl/2018/01/03/science.aao1710.DC1</a>
RELATED CONTENT	<a href="http://science.sciencemag.org/content/sci/early/2018/01/03/science.aan5951.full">http://science.sciencemag.org/content/sci/early/2018/01/03/science.aan5951.full</a>
REFERENCES	This article cites 49 articles, 12 of which you can access for free <a href="http://science.sciencemag.org/content/early/2018/01/03/science.aao1710#BIBL">http://science.sciencemag.org/content/early/2018/01/03/science.aao1710#BIBL</a>
PERMISSIONS	<a href="http://www.sciencemag.org/help/reprints-and-permissions">http://www.sciencemag.org/help/reprints-and-permissions</a>

Use of this article is subject to the [Terms of Service](#)